Discover investment opportunities in Top 20 Stocks Under $12 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 20 Stocks Under $12 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 20 Stocks Under $12 using our Smart AI Filter.
7 stocks found for "Top 20 Stocks Under $12"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.96 | ±100.0% | -0.1 | 0.00% | |||
1.05 | ±36.3% | 8.2 | 9.82% | |||
1.00 | ±57.1% | 11.5 | 0.00% | |||
0.88 | ±63.7% | -4.8 | 0.00% | |||
1.79 | ±66.5% | 4.1 | 0.00% | |||
0.61 | ±38.9% | 6.7 | 5.08% | |||
0.87 | ±39.6% | 11.9 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Merely a year ago, Coty Inc. stock (NYSE: COTY) was priced around $10, but it now hovers close to $4, having declined more than 50% from its peak. This significant drop is indicative of more than just market fluctuations—it highlights the pressures that are heavily impacting one of the largest beauty firms globally.
Read moreNovo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx Holdings Inc. to offer it at the same price at US pharmacies. Bloomberg's Madison Muller reports.
Read moreAs a result of the changing EV landscape under President Donald Trump, U.S. automakers are evaluating their product lineups and calculating the dollar impacts. Tesla CEO Elon Musk said during the automaker's latest earnings call that the company is in a "weird transition period" as it deals with losing EV incentives in the U.S.
Read moreQ: What are some potential growth prospects for Ford Motor Company (F) in this price range?
A: Ford Motor Company (F) has been focusing on electric vehicle (EV) development, with key investments in battery technology and partnerships to enhance production capacity. This strategic direction aligns with global trends in automotive electrification and may offer growth opportunities despite price competition.
Q: How does Coty Inc. (COTY) align with value investment strategies within the cosmetics industry?
A: Coty Inc. (COTY) trades at a price that some consider undervalued given its brand portfolio and recent restructuring efforts. Investors looking for potential underpriced assets in consumer goods may find Coty's ongoing transformation appealing.
Q: What economic factors could impact Nokia Corporation's (NOK) stock performance?
A: Nokia Corporation (NOK) may be influenced by developments in the 5G rollout, trade policies affecting telecom equipment, and competition from rivals like Ericsson. Technological advancements and infrastructure investments can also play a role in stock performance.
Q: Does GoPro Inc. (GPRO) offer investors potential for seasonal sales growth?
A: GoPro Inc. (GPRO) often experiences sales peaks during holiday seasons and new product launches. Its innovative camera technology caters to niche markets such as extreme sports, which may contribute to seasonal growth patterns.
Q: Are there risks associated with investing in Amneal Pharmaceuticals (AMRX)?
A: Amneal Pharmaceuticals (AMRX) faces industry-specific risks such as regulatory approvals, patent challenges, and generic drug market competition. Investors should evaluate the company's ability to navigate these challenges within the pharmaceutical sector.
Q: How might Rivian Automotive, Inc. (RIVN) impact the EV market despite its current stock price?
A: Rivian Automotive, Inc. (RIVN) focuses on electric trucks and SUVs, backed by substantial investments and partnerships. Its entry could shake up traditional automotive markets; however, execution risks and production scalability remain concerns.